Current controversies, such as the choice of antithrombin during PCI, the duration of dual antiplatelet therapy (DAPT), and the identification of PCI candidates among stable CAD patients, will be explored during this one-hour webcast. The MATRIX Treatment Duration study compared outcomes with of bivalirudin and heparin use among 7,000 European ACS patients and also examined the impact of post- PCI bivalirudin infusion. Next, the OPTIDUAL trial examined the impact of DAPT use for up to 4 years after PCI in patients free of adverse events in the first year. Finally, the PLATFORM study examined the utility of CT-derived FFR for patients with stable coronary artery disease.
Click Here to access this CME Program
November 23, 2015
May 23, 2016